Vivos Therapeutics, Inc. (VVOS) — 10-Q Filings

10-Q Filings (6)

• Vivos Revenue Jumps 20% Amid Widening Losses, SCN Acquisition — Nov 19, 2025 Risk: high
  Vivos Therapeutics, Inc. (VVOS) reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $13.619 million, up from
• Vivos Therapeutics Files Q2 2025 10-Q — Aug 19, 2025 Risk: medium
  Vivos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly Vivos BioTechnologies, Inc., is based in Littleton, CO, and o
• Vivos Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Vivos Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Vivos BioTechnologies, Inc., is based in Littleton, CO, and
• Vivos Therapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Vivos Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Vivos BioTechnologies, Inc., is based in Littleton, CO,
• Vivos Therapeutics Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Vivos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported revenue for the three months ended June 30, 2024, and the six
• Vivos Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk:
  Vivos Therapeutics, Inc. (VVOS) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Vivos Therapeutics, Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX